Presentation at PDA Minibus 2026
ALT-B4 Increases Drug Dispersion Rate and Reduces Swelling
"Enhanced Competitiveness for High-Dose SC Formulations"

Alteogen announced that in preclinical studies of large-volume subcutaneous (SC) injections conducted in collaboration with the U.S. medical device company Becton Dickinson, the application of its recombinant hyaluronidase 'ALT-B4' successfully reduced injection time and increased the rate of drug dispersion.


Taeyeon Jeon, CEO of Alteogen (second from left), is speaking at the panel discussion of the international conference 'PDA Minibus 2026' held in Dublin, Ireland, on the 21st and 22nd. Alteogen

Taeyeon Jeon, CEO of Alteogen (second from left), is speaking at the panel discussion of the international conference 'PDA Minibus 2026' held in Dublin, Ireland, on the 21st and 22nd. Alteogen

View original image

On May 26, Alteogen stated that it had presented joint preclinical data on large-volume subcutaneous injections with Becton Dickinson at the international conference 'PDA Minibus 2026,' held in Dublin, Ireland, on May 21 and 22.


This study evaluated drug delivery speed and subcutaneous tissue changes by applying Alteogen's recombinant hyaluronidase ALT-B4 to BD's wearable injector, the '10mL BD Libertas™'.


Analysis of the preclinical study using a pig model demonstrated that the 10mL large-volume formulation mixed with ALT-B4 improved abdominal injection time and injection rate compared to the formulation without ALT-B4. Ultrasound and CT analysis showed that the application of ALT-B4 increased the rate of drug dispersion within subcutaneous tissue and that swelling at the injection site subsided more quickly.



Taeyeon Jeon, CEO of Alteogen, stated, "Through the BD preclinical results, we have reaffirmed the competitiveness of ALT-B4," adding, "We expect it to become a key drug delivery solution amid the trend of expanding high-dose biopharmaceutical development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing